ArticleTherapeutic advances in neurological disorders2021

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.

Ludwig Kappos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.